Literature DB >> 15859515

Detection of p16 hypermethylation in gastric carcinomas using a seminested methylation-specific PCR.

Peng Hou1, Mei-Ju Ji, Jia-Yao Shen, Nong-Yue He, Zu-Hong Lu.   

Abstract

Aberrant DNA methylation of a CpG site is among the earliest and most frequent alterations in various tumors including gastric carcinoma. The aim of this study is to detect tumor-associated aberrant hypermethylation of the p16 gene from 60 gastric tumor and corresponding normal tissues using a seminested methylation-specific PCR (MSP). The results indicated that hypermethylation of the p16 gene could be detected in 80% (48/60) of the gastric tumor samples from the first PCR. However, the frequency increased significantly to 86.7% (52/60) of the gastric tumor samples after the second PCR. These results show that this technique increases the sensitivity of detecting p16 hypermethylation from tumor samples. Furthermore, the aberrant methylation of p16 was observed in all of the stages, confirming that this epigenetic alteration is an early event during gastric carcinogenesis. Clinicopathologic parameters such as age, sex, and histological differentiation of GC were not significantly associated with the methylation status.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15859515     DOI: 10.1007/s10528-005-1062-8

Source DB:  PubMed          Journal:  Biochem Genet        ISSN: 0006-2928            Impact factor:   1.890


  2 in total

1.  Methylation-dependent activation of CDX1 through NF-κB: a link from inflammation to intestinal metaplasia in the human stomach.

Authors:  Tilman T Rau; Anja Rogler; Myrjam Frischauf; Andreas Jung; Peter C Konturek; Arno Dimmler; Gerhard Faller; Bettina Sehnert; Wael El-Rifai; Arndt Hartmann; Reinhard E Voll; Regine Schneider-Stock
Journal:  Am J Pathol       Date:  2012-06-27       Impact factor: 4.307

2.  Clinical potential of DNA methylation in gastric cancer: a meta-analysis.

Authors:  Nur Sabrina Sapari; Marie Loh; Aparna Vaithilingam; Richie Soong
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.